Extended-release of chlorpromazine intercalated into montmorillonite clays

Drugs are rarely defined by a single act in a disease treatment but often elicit a cure with few side effects. In this respect, recent clinical analyses of treatment with antipsychotic drugs such as chlorpromazine (CPZ) show that high dose of CPZ leads to severe extrapyramidal side effects. To address the incidence of these side effects, CPZ was incorporated into montmorillonite (MMt) clay in order to gradually release it over a prolonged period. As a consequence of a lamellar structure and biocompatibility, MMt is mainly used as nanocarrier for the controlled release of several chemical drugs. XRD, FT-IR, DSC-TGA and SEM techniques were used to characterize the structure of the prepared formulation, all confirming the successful intercalation of CPZ into MMt interlayer spaces. The potential application was verified through release of CPZ from CPZ/MMt formulation. The drug release profile indicated that the release of the intercalated CPZ was slower than the release of the CPZ lonely (pure). The presence of the MMt clay in CPZ/MMt capsule beads reduced the release rate and upheld the sustained release of the model drug for a longer period. To elucidate the release mechanism of CPZ from CPZ/MMt formulation, the release data were subjected to release kinetic. Thus, the results suggested the feasibility of the use of MMt clay materials for controlled manner of drugs, and thereby, a sustained release is favorable and side effects reduced. [Display omitted] •Chlorpromazine was successfully intercalated into montmorillonite clay.•Physico-chemical features of the new composite were studied.•Potential application was investigated by release of CPZ in gastric environment.